Lixte Biotechnology terminates exclusive MDS license with Moffitt; no termination fee

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Received counter-signed termination letter on Oct 4, 2023, effective Sept 30, 2023.
No termination fee or further payments owed by Lixte under the license agreement.
Company had previously disclosed discontinuation of MDS development in June 30, 2023 10-Q.
License originally granted in August 2018 covering patents for myelodysplastic syndrome.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. terminated Exclusive License Agreement with H. Lee Moffitt Cancer Center and Research Institute, Inc. valued at No termination fee payable; no further payments owed by Company. (effective 2023-09-30).

Action: termination
Agreement: license
Counterparty: H. Lee Moffitt Cancer Center and Research Institute, Inc.
Value: No termination fee payable; no further payments owed by Company.
Effective: 2023-09-30

Exact text from the filing

On October 4, 2023, Lixte Biotechnology Holdings, Inc. (the “Company”) received a counter-signed termination letter dated September 29, 2023 (the “Termination Letter”) with respect to the Exclusive License Agreement dated August 20, 2018 (the “License Agreement”) between the Company and H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), effective September 30, 2023.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-035716

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.